1995
(BETA) News Briefs: Roche and Merck Begin Expanded Access Programs for Protease Inhibitor DrugsBulletin of Experimental Treatments for AIDS, No. 26 September 1995Ronald Baker, PhD
(BETA) Debate on FDA Reform: A View from the U.S. SenateBulletin of Experimental Treatments for AIDS, No. 26; September 1995Ronald Baker, PhD
(BETA) Wasting Syndrome: Decreased food intake, not increased metabolism, causes weight lossBulletin of Experimental Treatments for AIDS, No. 26; September 1995Harvey Bartnof, MD
(BETA) Opportunistic Infections: Paclitaxel Treatment for Kaposi's SarcomaBulletin of Experimental Treatments for AIDS, No. 26; September 1995Harvey Bartnof, MD
(BETA) Opportunistic Infections: New Guidelines for Pediatric PCP PreventionBulletin of Experimental Treatments for AIDS, No. 26; September 1995Harvey Bartnof, MD
(BETA) Opportunistic Infections: Granulocyte Colony Stimulating Factor (G-CSF) Increases White Blood Cell Killing Abilities and NumbersBulletin of Experimental Treatments for AIDS, No. 26; September 1995Harvey Bartnof, MD
(BETA) Opportunistic Infections: Octreotide May Not Benefit All AIDS-Associated DiarrheaBulletin of Experimental Treatments for AIDS, No. 26; September 1995Harvey Bartnof, MD
(BETA) Opportunistic Infections: Oral Ganciclovir Beneficial for Preventing Primary and Recurrent CMV RetinitisBulletin of Experimental Treatments for AIDS, No. 26 September 1995Harvey Bartnof, MD
(BETA) Opportunistic Infections: Indoor Potted Plant Soil is a Source of Mycobacterium aviumBulletin of Experimental Treatments for AIDS, No. 26; September 1995Harvey Bartnof, MD
(BETA) AZT Therapy Not Just for HIV/AIDSBulletin of Experimental Treatments for AIDS, No. 26; September 1995Harvey Bartnof, MD
(BETA) Anti-HIV Therapies: When to Start AZT: Not Early but Very EarlyBulletin of Experimental Treatments for AIDS, No. 26; September 1995Harvey Bartnof, MD
(BETA) Immune Therapies: Expansion of CD4 Lymphocytes Outside the BodyBulletin of Experimental Treatments for AIDS, No. 26; September 1995Harvey Bartnof, MD
(BETA) Vaccine Research: HIV-2 Infection Partially Protects against HIV-1 Infection - Significant implications for HIV-1 vaccine developmentBulletin of Experimental Treatments for AIDS, No. 26; September 1995Harvey Bartnof, MD
(BETA) Vaginal Candidiasis and Other Types of VaginitisBulletin of Experimental Treatments for AIDS, No. 26; September 1995Leslie Hanna, Associate Editor of BETA.
(BETA) Advances in Treatments for Cytomegalovirus RetinitisBulletin of Experimental Treatments for AIDS, No. 26; September 1995Mark Bowers; Treatment Hotline Manager at Project Inform and a frequent contributor to BETA.
(BETA) HIV: A New Model for Treatment -- Vitamins, Minerals and Trace ElementsBulletin of Experimental Treatments for AIDS, No. 26 September 1995Mary Romeyn, MD
(BETA) News Briefs: Who Has Budget Authority over AIDS Research?Bulletin of Experimental Treatments for AIDS, No. 26 September 1995Ronald Baker, PhD
(BETA) News Briefs: NIH Research Funding Survives First-Round Budget CutsBulletin of Experimental Treatments for AIDS, No. 26 September 1995Ronald Baker, PhD
(BETA) News Briefs: Senate Reauthorizes Ryan White FundsBulletin of Experimental Treatments for AIDS, No. 26 September 1995Ronald Baker, PhD
(BETA) News Briefs: Transmission of Parasite in San Francisco Drinking Water?Bulletin of Experimental Treatments for AIDS, No. 26 September 1995Ronald Baker, PhD
(BETA) News Briefs: Medicare May Not Reimburse for Certain AIDS and Cancer DrugsBulletin of Experimental Treatments for AIDS, No. 26 September 1995Ronald Baker, PhD
(BETA) News Briefs: XI International Conference on AIDS: Call for Abstracts and RegistrationBulletin of Experimental Treatments for AIDS, No. 26 September 1995Ronald Baker, PhD
(BETA) News Briefs: Controversy over Role of New Herpes Virus in Kaposi's SarcomaBulletin of Experimental Treatments for AIDS, No. 26 September 1995Ronald Baker, PhD
(BETA) News Briefs: Studies of Rifabutin to Prevent TuberculosisBulletin of Experimental Treatments for AIDS, No. 26 September 1995Ronald Baker, PhD
(BETA) News Briefs: Should All Blood Be Screened for HHV-6?Bulletin of Experimental Treatments for AIDS, No. 26 September 1995Ronald Baker, PhD
(BETA) News Briefs: HHV-6 Linked to Multiple SclerosisBulletin of Experimental Treatments for AIDS, No. 26 September 1995Ronald Baker, PhD
(BETA) News Briefs: Valaciclovir (Valtrex) Approved for Herpes Zoster (Shingles)Bulletin of Experimental Treatments for AIDS, No. 26 September 1995Ronald Baker, PhD
(BETA) News Briefs: Foscarnet Approved to Treat Acyclovir-Resistant Herpes SimplexBulletin of Experimental Treatments for AIDS, No. 26 September 1995Ronald Baker, PhD
(BETA) News Briefs: Chiron Seeks Approval for Ganciclovir ImplantBulletin of Experimental Treatments for AIDS, No. 26 September 1995Ronald Baker, PhD
(BETA) News Briefs: FDA Approves Baboon Bone Marrow Transplant for AIDS PatientBulletin of Experimental Treatments for AIDS, No. 26 September 1995Ronald Baker, PhD
(BETA) News Briefs: FDA Approves Access to Thalidomide through ManufacturerBulletin of Experimental Treatments for AIDS, No. 26 September 1995Ronald Baker, PhD
(BETA) News Briefs: HIV-2 May Protect against HIV-1Bulletin of Experimental Treatments for AIDS, No. 26 September 1995Ronald Baker, PhD
(BETA) News Briefs: Renewed Interest in d4TBulletin of Experimental Treatments for AIDS, No. 26 September 1995Ronald Baker, PhD
(BETA) News Briefs: Hydroxyurea plus AZT or ddIBulletin of Experimental Treatments for AIDS, No. 26 September 1995Ronald Baker, PhD
(BETA) News Briefs: Other Uses for AZTBulletin of Experimental Treatments for AIDS, No. 26 September 1995Ronald Baker, PhD
(BETA) News Briefs: AZT Confers Benefit during Primary InfectionBulletin of Experimental Treatments for AIDS, No. 26 September 1995Ronald Baker, PhD
(BETA) News Briefs: AZT plus 3TC is Effective CombinationBulletin of Experimental Treatments for AIDS, No. 26 September 1995Ronald Baker, PhD
(BETA) News Briefs: Glaxo Files for Accelerated Approval of 3TC plus AZTBulletin of Experimental Treatments for AIDS, No. 26 September 1995Ronald Baker, PhD
(BETA) News Briefs: Roche Investigators Say Invirase Does Not Cause Cross-Resistance to Other Protease InhibitorsBulletin of Experimental Treatments for AIDS, No. 26 September 1995Ronald Baker, PhD
(BETA) News Briefs: Study of Enhanced Saquinavir Formulation Open to EnrollmentBulletin of Experimental Treatments for AIDS, No. 26 September 1995Ronald Baker, PhD
(BETA) News Briefs: Roche Files for Accelerated Approval of SaquinavirBulletin of Experimental Treatments for AIDS, No. 26 September 1995Ronald Baker, PhD
(BETA) News Briefs: Abbott Agrees to Expanded Access for RitonavirBulletin of Experimental Treatments for AIDS, No. 26 September 1995Ronald Baker, PhD
(BETA) News Briefs: Genetics Institute Halts Study of Interleukin-12 for Kidney CancerBulletin of Experimental Treatments for AIDS, No. 26 September 1995Ronald Baker, PhD
BETA News Briefs: Wider Access to Human Growth HormoneBulletin of Experimental Treatments for AIDS, No. 26 September 1995Ronald Baker, PhD
Copyright © 1995 - San Francisco AIDS Foundation. Reproduced by permission. Reproduction of this article (other than one copy for personal reference) must be cleared through BETA: PO Box 426182, San Francisco, CA 94142-6182. Tel: 415 487 8060 Fax: 415 487 8069 URL: http://www.sfaf.org/beta E-mail: beta@sfaf.org
This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1990,2001. ÆGiS.